Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aquavit Pharmaceuticals Forms Alliance Partnership with Accelrys

Published: Sunday, October 14, 2012
Last Updated: Sunday, October 14, 2012
Bookmark and Share
Aquavit to utilize the Accelrys Enterprise Platform to develop advanced medical software for cutting-edge personalized medicine.

Aquavit Pharmaceuticals, Inc. and Accelrys Software Inc. (NASDAQ: ACCL), a leader in scientific innovation lifecycle management software, have formed an alliance partnership towards the development of Aquavit's PITO-001 and MAV-403 products.  The partner agreement was signed on September 12, 2012.  Under the terms of the partnership, Aquavit will utilize the scientifically aware Accelrys Enterprise Platform to develop advanced medical software for cutting-edge personalized medicine.

"It is an exciting opportunity for both companies.  As a leading global provider of enterprise scientific informatics software, Accelrys is the ideal partner to accelerate achievement of Aquavit's vision.  Having our products powered by the Accelrys Enterprise Platform will support our market leading science," said Sobin Chang, Aquavit's Chief Executive Officer.

"We are pleased to be partnering with Aquavit Pharmaceuticals to help accelerate the development of innovative personalized treatments," said Sanjay Gupta, Vice President of Corporate Development at Accelrys.  "The Accelrys Enterprise Platform will advance these initiatives by providing unparalleled capabilities in managing end-to-end scientific workflows to achieve better outcomes."

This partnership will be led by Thomas S. Benjamin, Vice President of Technology at Aquavit Pharmaceuticals.  Mr. Benjamin's award winning research has appeared in The New York Times and The Wall Street Journal.  Mr. Benjamin said, "We aim to break new ground with the first-of-a-kind systems in our product lines.  We are thrilled to be integrating the powerful Accelrys Enterprise Platform into the development of our next-generation medical technologies."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Accelrys Announces 2012 US Tech Summit for IT Professionals
Fourth US Tech Summit for Accelrys customers will take place October 16-17 in New Jersey.
Sunday, October 21, 2012
Accelrys Announces Software Licensing Agreement with Gulf Coast Consortia
Tailored academic license defines new informatics standard for multi-center collaborative research and Cloud-based data sharing
Saturday, June 02, 2012
Accelrys Acquires VelQuest Corporation for $35 Million in Cash
Extends reach downstream in the lab-to-market value chain with addition of industry-leading lab execution and data capture software
Monday, March 19, 2012
Accelrys Acquires VelQuest
Accelrys adds paperless lab execution systems to portfolio with acquisition of VelQuest Corporation.
Friday, January 06, 2012
Nippon Shinyaku Selects and Deploys the Symyx Notebook by Accelrys
Accelrys Electronic Laboratory Notebook drives R&D efficiency and eases regulatory burdens
Monday, November 28, 2011
Leading Scientists to Present Computational and Informatics Solutions at Accelrys Science Forum Series
Seminars will feature top researchers discussing in silico solutions for pharmaceutical, biotech and chemicals R & D organizations.
Wednesday, October 10, 2007
Accelrys Launches NanoBiology Initiative
Initiative will bring together industry, government and academic experts to drive nanobiology innovation.
Wednesday, November 16, 2005
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!